ClinicalTrials.gg
Active, not recruitingNCT05392114Updated Dec 12, 2025

A Study to Assess the Long-Term Safety and Efficacy of Donidalorsen in the Prophylactic Treatment of Hereditary Angioedema (HAE)

A Phase 3 interventional study of Donidalorsen in Hereditary Angioedema, sponsored by Ionis Pharmaceuticals, Inc.. Active, not recruiting at 50 sites in 14 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2025-12-12.

Sponsored by Ionis Pharmaceuticals, Inc. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
154
Allocation
Not applicable
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 84 studies in Angioedemas, Hereditary with a site in United States — 12 open to participants now, 18 under way, 10 of them phase 3. Angioedemas, Hereditary · United States.

Enrollment
7th of 74
154 · median 57
Started
2022
with 7 others
Phase 3
38 of 84
6 open now
Primary completion
2026-12
later than 3 of 17 live
Registered
56th of 84
by date
Lead sponsor
5 of 84
Ionis Pharmaceuticals, Inc.

Among the 84 studies in Angioedemas, Hereditary with a site in United States, this one is the 7th largest by enrollment of the 74 interventional ones that give a count, is one of 8 that started in 2022, is one of 38 in phase 3, reaches primary completion later than 3 of the 17 other live ones, and was the 56th registered.

Angioedemas, Hereditary

171 studies on the registry are indexed under Angioedemas, Hereditary; 24 are open to participants now.

Browse Angioedemas, Hereditary studies →

Open to participants now

12 of the 84 studies in Angioedemas, Hereditary with a site in United States are open now. Recruiting first, the newest first:

7 more — sign in →

All 12 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 13 Angioedemas, Hereditary studies recruiting now, 9 (69%) set no upper age limit and 4 (31%) stop at 75 or younger; 7 take children under 18; 1 takes healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 84 studies in Angioedemas, Hereditary with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the long-term safety and efficacy of donidalorsen in people with HAE and the effects of donidalorsen on the number of HAE attacks and their impact on quality of life (QoL).

Read the detailed description

This is a Phase 3, multi-center, open-label, global study with donidalorsen in up to approximately 144 participants with HAE-1 (Type I) and HAE-2 (Type II). There are two groups in this study: 1) participants who roll over from another study of donidalorsen (open-label extension [OLE] participants), and 2) new participants who are not rolling over from another study of donidalorsen and were previously maintained on HAE prophylactic therapy with lanadelumab, berotralstat, or a C1-esterase inhibitor (C1-INH). The length of participation in the study is approximately 70 weeks for OLE participants and 76 weeks for other participants. Participants will receive donidalorsen in an Extended Treatment Period for up to an additional 104 weeks.

03

Conditions studied

  • Hereditary Angioedema

Keywords

  • HAE
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants and, as applicable, legally authorized representatives (i.e., parent(s)/legal guardian), must provide written and signed form (ICF).
  2. Participants must have access to, and the ability to use, ≥ 1 acute medication(s) (e.g., plasma-derived or recombinant C1-INH concentrate or a bradykinin receptor (BK) 2-receptor antagonist) to treat angioedema attacks.

    Open-Label Extension Participants ONLY:

  3. Satisfactory completion of ISIS 721744-CS5 (randomized placebo-controlled index study) through Week 25 or participants who are allowed to exit ISIS 721744-CS5 study per protocol with an acceptable safety and tolerability profile.

    New (not previously on donidalorsen) Participants ONLY:

  4. Participants must be aged ≥ 12 years at the time of informed consent and, as applicable, assent.
  5. Participants must have a documented diagnosis of HAE-1/HAE-2.
  6. Participants must be on a stable dose (≥ 12 weeks) of prophylaxis treatment with lanadelumab or berotralstat or SC C1-esterase inhibitor prior to the Screening Period.

Exclusion criteria

Exclusion Criteria

Open-Label Extension Participants:

  1. Have any new condition or worsening of an existing condition or change or anticipated change in medication.

    New (not previously on donidalorsen) Participants ONLY:

  2. Concurrent diagnosis of any other type of recurrent angioedema, including acquired, idiopathic angioedema or HAE with normal C1-INH (also known as HAE Type III).
  3. Anticipated change in the use of concurrent androgen or tranexamic acid prophylaxis used to prevent angioedema attacks.
  4. Any clinically-significant abnormalities in screening laboratory values.
  5. within 5 years of Screening, except for non-melanoma skin cancers, cervical in situ carcinoma, breast ductal carcinoma in situ, or stage 1 prostate carcinoma that has been successfully treated.
  6. to the active substance (donidalorsen) or to any of the .
  7. Treatment with another drug (non-oligonucleotide) or biological agent within 1 month of Screening or 5 half-lives of investigational agent, whichever is longer.
  8. Recent history of, or current drug or alcohol abuse.
  9. Participated in a prior donidalorsen study.
  10. Exposure to any of the following medications:

    1. Angiotensin-converting enzyme (ACE) inhibitors or any estrogen containing medications with systemic absorption.
    2. Oligonucleotides (including small interfering ribonucleic acid [siRNA]) within 4 months of Screening if single dose received, or within 12 months of Screening if multiple doses received. This exclusion does not apply to vaccines.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
154 participants (actual)

Study arms

  • Experimental
    OLE Participants

    Group 1 and Group 2 participants will be administered donidalorsen by SC injection for up to 157 weeks.

    Drug: Donidalorsen

Interventions

  • Donidalorsen will be administered by SC injection.

    Also known as: ISIS 721744, IONIS-PKK-LRx

06

What researchers measure

Primary outcomes

  1. Percentage of Participants with at Least One Treatment-emergent Adverse Event (TEAE), Graded by Severity

    Time frame: Up to approximately 70 weeks, plus 104 weeks for Group 1; up to approximately 76 weeks, plus 104 weeks for Group 2

Secondary outcomes

  1. Time-normalized Number of Investigator-confirmed HAE Attacks (per Month)

    Time frame: Week 1 to Week 157 for Group 1 and Group 2

  2. Percentage of Investigator-confirmed HAE Attack-free Participants

    Time frame: Week 1 to Week 157 for Group 1 and Group 2

  3. Time-normalized Number of Moderate or Severe Investigator-confirmed HAE Attacks (per Month)

    Time frame: Week 1 to Week 157 for Group 1 and Group 2

  4. Number of Investigator-confirmed HAE Attacks Requiring Acute Therapy

    Time frame: Week 1 to Week 157 for Group 1 and Group 2

  5. Angioedema Quality of Life (AE-QoL) Questionnaire Total Score

    The AE-QoL questionnaire is a validated tool to assess symptom-specific health-related QOL impairment in participants suffering from recurrent angioedema. The AE-QoL is a self-administered questionnaire comprising 17 questions across 4 domains: functioning, fatigue/mood, fears/shame, and food. The responses are scored from 1 to 5 where, 1 = never, 2 = rarely, 3 = sometimes, 4 = often, 5 = very often. Total and domain scores range from 0 to 100, with higher scores indicating greater impairment.

    Time frame: Up to 157 weeks for Group 1 and Group 2

07

Study locations

50 sites
  • Ionis Investigative Site
    Paradise Valley, Arizona 85253, United States
  • Ionis Investigative Site
    La Jolla, California 92037, United States
  • Ionis Investigative Site
    Santa Monica, California 90404, United States
  • Ionis Investigative Site
    Walnut Creek, California 94598, United States
  • Ionis Investigative Site
    Tampa, Florida 33613, United States
  • Ionis Investigative Site
    Kansas City, Kansas 66103, United States
  • Ionis Investigative Site
    Boston, Massachusetts 02114, United States
  • Ionis Investigative Site
    Ann Arbor, Michigan 48109, United States
  • Ionis Investigative Site
    Detroit, Michigan 48202, United States
  • Ionis Investigative Site
    St Louis, Missouri 63141, United States
  • Ionis Investigative Site
    Mooresville, North Carolina 28117, United States
  • Ionis Investigative Site
    Cincinnati, Ohio 45236, United States
  • Ionis Investigative Site
    Columbus, Ohio 43235, United States
  • Ionis Investigative Site
    Hershey, Pennsylvania 17033, United States
  • Ionis Investigative Site
    Dallas, Texas 75231, United States
  • Ionis Investigative Site
    Murray, Utah 84107, United States
  • Ionis Investigative Site
    Edegem, 2650, Belgium
  • Ionis Investigative Site
    Sofia, 1431, Bulgaria
  • Ionis Investigative Site
    Sofia, 1680, Bulgaria
  • Ionis Investigative Site
    Ottawa, Ontario K1H 1E4, Canada
  • Ionis Investigative Site
    Edmonton, AB T6G 1Z1, Canada
  • Ionis Investigative Site
    La Tronche, 38700, France
  • Ionis Investigative Site
    Marseille, 13385, France
  • Ionis Investigative Site
    Paris, 75012, France
  • Ionis Investigative Site
    Berlin, 12203, Germany
  • Ionis Investigative Site
    Frankfurt, 60590, Germany
  • Ionis Investigative Site
    München, 81675, Germany
  • Ionis Investigative Site
    Ashkelon, 7830604, Israel
  • Ionis Investigative Site
    Haifa, 3104802, Israel
  • Ionis Investigative Site
    Tel Aviv, 6423906, Israel
  • Ionis Investigative Site
    Catania, 95123, Italy
  • Ionis Investigative Site
    Naples, 80131, Italy
  • Ionis Investigative Site
    Padova, 35128, Italy
  • Ionis Investigative Site
    Palermo, 90146, Italy
  • Ionis Investigative Site
    San Donato Milanese, 20097, Italy
  • Ionis Investigative Site
    Amsterdam, 1105, Netherlands
  • Ionis Investigative Site
    Groningen, 9713 AP, Netherlands
  • Ionis Investigative Site
    Krakow, 31-501, Poland
  • Ionis Investigative Site
    San Juan, PR 00927, Puerto Rico
  • Ionis Investigative Site
    Barcelona, 08035, Spain
  • Ionis Investigative Site
    Barcelona, 08907, Spain
  • Ionis Investigative Site
    Madrid, 28046, Spain
  • Ionis Investigative Site
    Seville, 41013, Spain
  • Ionis Investigative Site
    Valencia, 46026, Spain
  • Ionis Investigative Site
    Altındağ, 06230, Turkey (Türkiye)
  • Ionis Investigative Site
    Bornova, 35100, Turkey (Türkiye)
  • Ionis Investigative Site
    Istanbul, 34093, Turkey (Türkiye)
  • Ionis Investigative Site
    Birmingham, B9 5SS, United Kingdom
  • Ionis Investigative Site
    Bristol, BS10 5NB, United Kingdom
  • Ionis Investigative Site
    London, E1 2ES, United Kingdom
08

References and documents

Publications

  • Lumry WR, Tachdjian R, Craig T, Karakaya G, Gelincik A, Stobiecki M, Jacobs JS, Gokmen NM, Reshef A, Manning ME, Grammatikos A, Giardino F, Guilarte M, Baptist AP, Bordone L, Newman KB, Treadwell S, Lin T, Yarlas A, Riedl MA, Cohn DM. Donidalorsen for Long-Term Prophylaxis of Hereditary Angioedema Attacks: Results from the OASISplus Open-Label Extension Cohort at Year 1. J Asthma Allergy. 2026 Feb 23;19:592079. doi: 10.2147/JAA.S592079. eCollection 2026. PubMed 41767175 ↗
  • Riedl MA, Bernstein JA, Jacobs JS, Craig T, Banerji A, Perego F, Lumry WR, Wedner HJ, Gierer S, Manning ME, Bordone L, Treadwell S, Lin T, Newman KB, Yarlas A, Cohn DM. Donidalorsen Treatment of Hereditary Angioedema in Patients Previously on Long-Term Prophylaxis. J Allergy Clin Immunol Pract. 2025 Sep;13(9):2381-2389.e3. doi: 10.1016/j.jaip.2025.06.018. Epub 2025 Jul 17. PubMed 40673861 ↗

Individual participant data

Plan to share: Yes — Ionis may share anonymized individual participant data, aggregated clinical data, and other types of data that support the results in this study. Data requests from qualified researchers will be considered once all three of the following criteria are met: (1) 12 months from marketing approval of the study drug in both the United States and European Union; (2) 18 months from conclusion of the study; and (3) 6 months from publication of study article. Access would be via a secure environment and is contingent upon approval of a research proposal and entry into an appropriate data use agreement. Requests to access data can be submitted via the website https://vivli.org/ourmember/ionis/.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2022 (actual). Primary completion is estimated for Dec 2026, 53 months after the start.

Of 46 industry-sponsored phase 3 interventional studies under Angioedemas, Hereditary, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 33. This study's planned 53 months is above that.

Counting every sponsor, half of 46 studies reached it within 22 months; a quarter within 16 and three quarters within 33.

How these figures are worked out, and which studies are left out of them.

Registered
May 23, 2022
First posted
May 26, 2022
StartActual
Jul 13, 2022
Primary completionEst.
Dec 2026
CompletionEst.
Mar 2027
Last update
Dec 12, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05392114
Responsible party
Sponsor
First posted
May 26, 2022
Start date
Jul 13, 2022
Primary completion
Dec 2026 (estimated)
Completion
Mar 2027 (estimated)
Last update
Dec 12, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Donidalorsen

Start the discussion